Novo Nordisk’s focus on diabetes and obesity shape its business development work, but the company is also exploring other areas. Top Novo Nordisk M&A executive John McDonald discussed his company’s strategy during a session at the BIO conference in San Diego.

The post At BIO, Novo Nordisk’s Top Dealmaker Talks M&A Strategy and What’s Next After GLP-1s appeared first on MedCity News.

BIO’s first annual report on diversity in the workplace found room for improvement, as biotech workforces – especially at the executive level – were found to not represent the U.S. population. The report was based on a survey of nearly 100 companies in late spring 2019.

The post Biotech falls short on diversity in workplace, exec teams, according to report appeared first on MedCity News.

Experts at last week’s BIO meeting in Philadelphia discussed the long-term implications of many gene therapies hitting the market, and ways their prices could be lowered so they’d be more cost-effective.

The post Could automating raw materials production bring down gene therapy prices? appeared first on MedCity News.

At BIO Tuesday, panelists discussed the lack of racial, ethnic and gender diversity in clinical trials and its potential implications.

The post Building trust is key to improving diversity in clinical trials appeared first on MedCity News.

The post Party at BIO conference that featured topless dancers draws fire from organization appeared first on MedCity News.

It’s an incredible time for the life sciences, panelists at a Biotech Showcase session on Monday agreed. However, it comes with a catch: The greater the miracle, the greater the anguish when a patient can’t afford or can’t access the drug.

The post In an era of cures, price-prohibitive drugs are an even harder pill to swallow appeared first on MedCity News.

At the sixth annual BIO Patient and Health Advocacy Summit in Washington, D.C. this week, a discussion on clinical trial design explored some of the challenges of ensuring patient’s needs are balanced with those of drug developers and regulatory needs.

The post Why designing patient-centered clinical trials is like conducting an orchestra appeared first on MedCity News.

Drug pricing was destined to be a major topic, as manufacturers and payers continue to duke it out.

The post Microbiota, novel antibiotics, and of course drug pricing among #BIO2016 takeaways appeared first on MedCity News.

The post Will CAR-T deliver on the promise of widespread therapeutic improvement? appeared first on MedCity News.

Muhammad Ali announced many years ago that he suffered from Parkinson’s disease, but Dr. Bennet Omalu thinks differently, hypothesizing the boxer may have suffered from CTE.

The post BIO 2016: Concussions, Ali, FDA and synthetic biology appeared first on MedCity News.

Janelle R. Anderson, PhD, Managing Partner of CTI Life Sciences Fund, has started a new podcast in which she interviews business leaders within the life sciences and venture capital.

The post Life sciences meets venture capital in new podcast: ‘Human Proof of Concept’ appeared first on MedCity News.

The post In defense of Martin Shkreli appeared first on MedCity News.

The post Martin Shkreli: BIO, PhRMA are self-serving hypocrites appeared first on MedCity News.

The post #BIO2015: BIO’s now “Biotechnology Innovation Organization” (Groan) appeared first on MedCity News.

The post Report: How are venture dollars distributed among disease and clinical trial phase? appeared first on MedCity News.

The post Bad timing for good news? New chart shows FDA is flying through its drug reviews appeared first on MedCity News.

The post What could Uber do to the future of drugmaking? appeared first on MedCity News.

The post Does biotech win if VCs get a better chance at SBIR? appeared first on MedCity News.

The post Plenty of ideas to boost biotech education. Now let’s focus on the ones that work appeared first on MedCity News.